JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant (IMVT) to $33 from $37 and keeps an Overweight rating on the shares. The firm updated the company’s model.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- 3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts
- Immunovant’s Batoclimab Shows Promising Results in Phase 2 Study for Graves’ Disease, Earning Buy Rating
- Immunovant’s Promising Clinical Data and Strategic Advancements Drive Buy Rating
- Immunovant Announces Promising Graves’ Disease Study Results
- Immunovant: 80% of patients demonstrate response in Graves’ disease trial